Frankfurt - Delayed Quote EUR

Genfit S.A. (XUPB.F)

3.8000
-0.0400
(-1.04%)
At close: May 8 at 9:23:47 AM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
67,002
67,002
28,565
20,195
80,069
Cost of Revenue
300
300
341
251
162
Gross Profit
66,702
66,702
28,224
19,944
79,907
Operating Expense
63,476
63,476
55,389
47,259
47,536
Operating Income
3,226
3,226
-27,165
-27,315
32,371
Net Non Operating Interest Income Expense
-2,170
-2,170
-1,419
-3,676
30,944
Other Income Expense
791
791
72
7,157
6,157
Pretax Income
1,847
1,847
-28,514
-23,836
69,474
Tax Provision
340
340
380
-116
2,215
Net Income Common Stockholders
1,507
1,507
-28,894
-23,719
67,259
Diluted NI Available to Com Stockholders
1,507
1,507
-28,894
-23,719
67,259
Basic EPS
0.45
0.03
-0.58
-0.48
1.51
Diluted EPS
0.37
0.03
-0.58
-0.48
1.23
Basic Average Shares
55,030.8020
50,233.3330
49,700.2230
49,414.5830
44,542.3840
Diluted Average Shares
55,030.8020
50,233.3330
49,700.2230
49,414.5830
54,682.1140
Total Operating Income as Reported
3,281
3,281
-26,580
-27,289
31,816
Total Expenses
63,776
63,776
55,730
47,510
47,698
Net Income from Continuing & Discontinued Operation
1,507
1,507
-28,894
-23,719
67,259
Normalized Income
861.6091
861.6091
-28,948
-30,841.1698
61,298.3001
Interest Income
1,786
1,786
1,709
137
274
Interest Expense
4,747
4,747
4,624
4,410
4,955
Net Interest Income
-2,170
-2,170
-1,419
-3,676
30,944
EBIT
6,594
6,594
-23,890
-19,426
74,429
EBITDA
8,318
8,318
-22,236
-17,594
77,171
Reconciled Cost of Revenue
300
300
341
251
162
Reconciled Depreciation
1,724
1,724
1,654
1,832
2,742
Net Income from Continuing Operation Net Minority Interest
1,507
1,507
-28,894
-23,719
67,259
Total Unusual Items Excluding Goodwill
791
791
72
7,157
6,157
Total Unusual Items
791
791
72
7,157
6,157
Normalized EBITDA
7,527
7,527
-22,308
-24,751
71,014
Tax Rate for Calcs
0.0002
0.0002
0.0003
0
0
Tax Effect of Unusual Items
145.6091
145.6091
18
34.8302
196.3001
12/31/2021 - 11/4/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

328.SG MeiraGTx Holdings PLC
4.8000
+0.42%
 
22Z.SG Zealand Pharma A/S
59.96
-0.40%
 
25I.SG ImmuPharma PLC
0.0295
-1.67%
 
BT3.BE Lineage Cell Therapeutics Inc
0.3840
+2.67%
 
6XC.F Soleno Therapeutics, Inc.
64.05
+2.89%
 
SCP.F Scancell Holdings plc
0.0950
-1.04%
 
AYJ.HA Valneva SE
2.8500
-1.99%
 
PI3.DU Gubra AS
51.00
-1.26%
 
2L9.SG Blueprint Medicines Corp
88.12
+1.66%
 
IM8N.SG Insmed Incorporated
58.00
-1.69%